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The history of medicine provides perspective invisible from PubMed. Past theories and
practices seem risible until one considers which moderns medical “facts” will amuse future
generations. Neurological disorders have been particularly difficult to resolve since anatomy
and function are so complex. Primitive societies blamed the gods for seizures and strokes.
Disease causality was eventually internalized, but localization of neural function and
dysfunction remained poor for centuries, wandering through the uterus (hysteria) and heart
(emotions) among other organs while en route to the nervous system. Then, during the
mid-20th century Freudian era, neurological disorders without visible localizing lesions
(including movement disorders, autism, and schizophrenia), were often attributed to neurotic
reactions to psychological traumas rather than to neurological disease. Imperfect mothers
figured prominently. These dead-end theories still circulate in some cultures, but have faded
in western medicine as identification of cellular and molecular underpinnings of neurological
conditions map the path towards diagnosis and cure. We are witnessing such a transition in the
complex regional pain syndrome (CRPS).
CRPS certainly seemed suspicious. How could a minor or healed limb injury cause pain,
swelling, abnormal color and temperature, disordered sweating and movement, for months or
even years? And the sex ratio among patients (consistently ≥ 75% women) furthered suspicions
of hysteria or neurosis in physicians (consistently ≥ 75% men). In the 1990s Dutch surgeon/
scientist, R.J.A. Goris and his coworkers pioneered modern study of CRPS-I, the subtype then
thought not to involve nerve injury. In addition to large-scale phenotyping [17], they identified
the first evidence of nerve injuries [16] and conducted controlled treatment trials [11] among
other achievements. Furthered support for biological causality came from discovering high
levels of pro-inflammatory cytokines in skin, cerebrospinal fluid, and blood of CRPS-I patients
[2,6,15], and identification of microcirculatory abnormalities including hypoxia and
endothelial dysfunction [8,13]. Confirmation of chronic focal axonal injuries in CRPS-I [1,
10] reunited the CRPS-I and II subtypes.
Twenty-first century electronic medical charts now permit data-mining from larger and more
representative populations then can be recruited from pain-clinics, although this approach is
still limited by definitional and diagnostic vagueness. The first such study [12] reminded us
that most CRPS-I patients recover - a welcome antidote to pervasive pessimism. Recovery can
also be inferred from the fact that CRPS prevalence peaks in midlife, rather than continually
increasing with age as would be expected for a life-long non-fatal condition. The 2nd study
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used detailed diagnoses by pain specialists to improve figures on annual incidence [4]. This
same Dutch group now publishes the 3rd major population-based study [5], which compares
pre-existing diagnoses between 259 CRPS patients and 697 age- and gender-matched controls
with similar injuries not followed by CRPS. An electronic database of general practice visits
for 800,000 Dutch patients was searched using a careful case-control approach. The finding of
no link between prior psychiatric diagnosis and CRPS (odds ratio (OR) 1.17), confirms earlier
prospective studies to show that somatization and other pre-existing psychopathology is no
more a cause of CRPS than of stomach ulcers.
Several associations with peripheral problems were identified or confirmed. These make it less
likely that CRPS-I is a primary brain disorder, despite dramatic changes in cortical form and
function triggered by chronic peripheral pain. The strongest association, with neuropathy (OR
5.7), is as expected, given that the CRPS symptom complex was first characterized in patients
with major nerve injuries [9] and the recent finding of more subtle nerve injuries in CRPS-I
patients. The confirmation of links to migraine (OR 2.4) and a new association with asthma
(OR 3.0) may be important since we know far more about these conditions. Neurogenic
inflammation contributes to them all, and mast cells may mediate neural-immune connections
in CRPS [7] as they do in migraine and asthma. It is worth considering whether some asthma
and migraine treatments might be tried for CRPS. Corticosteroids, for instance, have been
effective in all 3 conditions [3]. Unexpected associations with menstrual disorders (OR 2.6)
and osteoporosis (OR 2.4) should spark further study.
De Mos et al. have identified new clinical links to CRPS and validated findings that implicate
inflammation, vasodysregulation, and axonal injury in CRPS pathogenesis. The challenge now
is to learn how these interact, because each can lead to the other, like the chicken and the egg.
For instance, distal axons are exquisitely vulnerable to energy deprivation, so
vasodysregulation or inflammation can trigger axonopathy. My working hypothesis is that
although specific patients may enter the CRPS rotary from different points, malfunctioning
small-fiber axons are central. Somatic and autonomic small-fibers densely innervate and
regulate tissues to maintain homeostasis. In CPRS, even subtle axonal injuries appear sufficient
to trigger remaining fibers into inappropriate firing and neuropeptide release. This combination
suffices to cause chronic pain, vasodysregulation, neurogenic inflammation as well as changes
in non-neural innervated tissues. Then, too much or too little small-fiber afferent input can
wreak additional havoc among central neurons and glia.
But epidemiological and biological research is entirely dependent upon careful characterization
and diagnosis of individual patients by physicians. This has been notoriously lax in CRPS.
Acceptance of CRPS as a neuropathic pain syndrome would provide new framework and rigor.
Applying the recently proposed revised definition of neuropathic pain as “pain arising as a
direct consequence of a lesion or disease affecting the somatosensory system” [14] would
reduce the number of patients without trauma, illness, or lesion being erroneously diagnosed
with CRPS. Classifying diagnoses as “definite, probable, or possible” according to the strength
of objective evidence permits different levels of certainty to be applied as needed in clinical
and research settings. It also conforms to clinical practice and to classification strategies proven
useful in other diseases. In the beginning, asthma too was thought to have strong psychological
antecedents, but unraveling asthma biology was what led to effective treatments. CRPS
research initiated and continued by Dutch scientists has brought us to the end of the beginning
in understanding CRPS, and offers hope for the beginning of the end.
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